In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Commentary|Videos|March 25, 2026
The Emergence of Bispecific Antibodies in Lymphoma
Author(s)Jennifer E. Amengual, MD
Fact checked by: Paige Britt
Epigenetic drugs boost CD20/CD19 and T-cell activity, making bispecific antibodies hit lymphoma harder—now moving into clinical trials.
Advertisement
In an interview with Targeted Oncology, Jennifer Amengual, MD, Herbert Irving associate professor of Medicine in the Division of Hematology and Oncology at the Columbia University Irving Medical Center, discusses the emergence of bispecific antibodies and how that effects epigenetic therapy in lymphoma treatment.
Advertisement
Related to this article
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
CELESTIMO trial shows mosunetuzumab plus lenalidomide boosts PFS in relapsed follicular lymphoma, supporting earlier-line outpatient, chemo-free care.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
2
SOT106 Receives New FDA FTD and ODD in Sarcoma
3
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
4
IMS 2026 Day 3 Recap: Etentamig Outperforms Standard Therapy in RRMM Trial
5